^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Published date:
12/16/2022
Excerpt:
In patients with PD-L1-high expression, OS was comparable between durvalumab and the EXTREME regimen. Durvalumab alone, and with tremelimumab, demonstrated durable responses and reduced TRAEs versus the EXTREME regimen in R/M HNSCC.
DOI:
10.1016/j.annonc.2022.12.008
Evidence Level:
Sensitive: B - Late Trials
Title:

Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer

Published date:
02/05/2021
Excerpt:
NON-SUPPORTIVE EVIDENCE: The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care, in the 1st-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours expressed high levels of PD-L1.
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

Published date:
05/13/2020
Excerpt:
Pts with low PD-L1 and low TMB had worse OS compared to pts with high PD-L1 or high TMB.
DOI:
10.1200/JCO.2020.38.15_suppl.6548
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with =25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Excerpt:
Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-high patients with R/M HNSCC
DOI:
10.1016/j.ejca.2018.11.015
Trial ID: